Related Experiment Video
Updated: Apr 23, 2026
11:35
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
58.9K
Precision medicine in chronic disease management: The multiple sclerosis BioScreen
Pierre-Antoine Gourraud1, Roland G Henry, Bruce A C Cree
1Department of Neurology, School of Medicine, University of California, San Francisco, San Francisco, CA.
Annals of Neurology
|September 30, 2014
Summary
MS BioScreen is a precision medicine tool for multiple sclerosis (MS) management. It transforms chronic disease care through digital medicine, enhancing data interpretation for better patient outcomes.
Area of Science:
- Digital medicine
- Precision medicine
- Translational research
Background:
- Multiple Sclerosis (MS) presents complex chronic disease management challenges.
- Dynamic patient data requires innovative clinical tools.
- Integrating information technology in medicine can transform healthcare delivery.
Purpose of the Study:
- To introduce MS BioScreen, a precision medicine application for multiple sclerosis (MS).
- To outline evolutionary phases for data display and interpretation in digital medicine tools.
- To highlight the potential of translational digital medicine in transforming medical practice.
Main Methods:
- Development of the MS BioScreen application.
- Introduction of three data display phases: visualization, contextualization, and actionable interpretation.
- Focus on clinician and patient interaction with the digital tool.
Main Results:
- MS BioScreen facilitates dynamic management of chronic MS.
- The three evolutionary phases guide data interpretation for healthcare providers, patients, and researchers.
- The tool supports standardization of data, evidence-based medicine, and shared decision-making.
Conclusions:
- MS BioScreen exemplifies the transformative potential of translational digital medicine.
- The application is expected to accelerate data standardization and promote evidence-based practices.
- Improved decision-making and patient outcomes are anticipated through enhanced data interpretation.
More Related Videos
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
9
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
9
01:16Therapeutic Drug Monitoring: Overview and Classification
622
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
622
01:29Pharmacogenomics: Identification of New Drug Targets
113
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113